| Bioactivity | (Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor[1]. |
| Invitro | 氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[1]。 |
| Name | (Rac)-Ruxolitinib-d9 |
| CAS | 2469553-67-9 |
| Formula | C17H9D9N6 |
| Molar Mass | 315.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Yaoyu CHEN, et al. Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor. Patent WO2021102258A1 |
(Rac)-Ruxolitinib-d9
CAS: 2469553-67-9 F: C17H9D9N6 W: 315.42
(Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibi
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.